CA2524074A1 - Oral composition to reduce cold symptoms and duration of same - Google Patents
Oral composition to reduce cold symptoms and duration of same Download PDFInfo
- Publication number
- CA2524074A1 CA2524074A1 CA002524074A CA2524074A CA2524074A1 CA 2524074 A1 CA2524074 A1 CA 2524074A1 CA 002524074 A CA002524074 A CA 002524074A CA 2524074 A CA2524074 A CA 2524074A CA 2524074 A1 CA2524074 A1 CA 2524074A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- weight percent
- zinc
- oral
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
An oral spray composition for preventing and/or reducing the symptoms of the common cold including a zinc formulation containing both zinc acetate and zinc gluconate to ensure sustained availability of increased amounts of ionizable zinc.
Claims (45)
1. A composition for delivering an active substance to at least one of an oral membrane, an oral pharyngeal membrane and a nasal membrane by administration through the oral cavity, said composition comprising:
a pharmaceutically acceptable carrier; and a zinc formulation comprising both zinc gluconate and zinc acetate.
a pharmaceutically acceptable carrier; and a zinc formulation comprising both zinc gluconate and zinc acetate.
2. The composition of claim 1, wherein said composition comprises zinc gluconate in an amount of about 32 to 35 mg/ml and zinc acetate in an amount of about 3 to 6 mg/ml.
3. The composition of claim 2, wherein said composition comprises zinc gluconate in an amount of about 33.4 mg/ml and zinc acetate in an amount of about 4.4 mg/ml.
4. The composition of claim 1, wherein said composition comprises free ionic zinc in an amount of about 5 to 7 mg/ml.
5. The composition of claim 4, wherein said composition comprises free ionic zinc in an amount of about 6.10 mg/ml.
6. The composition of claim 1, wherein said composition comprises an oral spray.
7. The composition of claim 1, wherein said pharmaceutically acceptable carrier comprises about 84 to 88 weight percent of said composition.
8. The composition of claim 7, wherein said pharmaceutically acceptable carrier comprises purified water.
9 9. The composition of claim 1, wherein said zinc formulation comprises about 3 to 6 weight percent of said composition.
10. The composition of claim 1 further comprising a stabilizer.
11. The composition of claim 10, wherein said stabilizer comprises glycerin.
12. The composition of claim 11, wherein said stabilizer comprises glycerin in an amount of about 0.8 to about 1.2 weight percent.
13. The composition of claim 1 further comprising a sweetener.
14. The composition of claim 13 wherein said sweetener comprises at least one of the following: fructose and dextrose.
15. The composition of claim 14 wherein said sweetener comprises fructose in an amount of about 8 to about 15 weight percent.
16. The composition of claim 1 further comprising a preservative.
17. The composition of claim 16, wherein said preservative comprises at least one of the following: benzalkonium chloride and benzyl alcohol.
18. The composition of claim 17, wherein said preservative comprises benzalkonium chloride in an amount of about 0.01 to about 0.02 weight percent.
19. The composition of claim 1 further comprising a flavor enhancer.
20. The composition of claim 19, wherein said flavor enhancer comprises about 0.5 to about 2 weight percent of said composition.
21. A composition for delivering an active substance to at least one of an oral, an oralpharyngeal, and a nasal membrane by administration through the mouth, said composition comprising:
about 84 to 99.9999 weight percent of a pharmaceutically acceptable carrier;
about 2 to about 4 weight percent of zinc gluconate; and about 0.2 to about 2.0 weight percent of zinc acetate.
about 84 to 99.9999 weight percent of a pharmaceutically acceptable carrier;
about 2 to about 4 weight percent of zinc gluconate; and about 0.2 to about 2.0 weight percent of zinc acetate.
22. The composition of claim 21, wherein said composition comprises free ionic zinc in an amount of about 5 to 7 mg/ml.
23. The composition of claim 22, wherein said composition comprises free ionic zinc in an amount of about 6.10 mg/ml.
24. The composition of claim 21, wherein said composition comprises an oral spray.
25. The composition of claim 21, wherein said pharmaceutically acceptable carrier comprises about 84 to 88 weight percent of said composition.
26. The composition of claim 25, wherein said pharmaceutically acceptable carrier comprises purified water.
27. The composition of claim 21, wherein said zinc formulation comprises about 2 to 6 weight percent of said composition.
28. The composition of claim 21 further comprising a stabilizer.
29. The composition of claim 28, wherein said stabilizer comprises glycerin.
30. The composition of claim 29, wherein said stabilizer comprises glycerin in an amount of about 0.8 to about 1.2 weight percent.
11~
11~
31. The composition of claim 21 further comprising a sweetener.
32. The composition of claim 31 wherein said sweetener comprises at least one of the following: fructose and dextrose.
33. The composition of claim 32 wherein said sweetener comprises fructose in an amount of about 8 to about 15 weight percent.
34. The composition of claim 21 further comprising a preservative.
35. The composition of claim 34, wherein said preservative comprise at least one of the following: benzalkonium chloride and benzyl alcohol.
36. The composition of claim 35, wherein said preservative comprises benzalkonium chloride in an amount of about 0.01 to about 0.02 weight percent.
37. The composition of claim 21 further comprising a flavor enhancer.
38. The composition of claim 37, wherein said flavor enhancer comprises about 0.5 to about 2 weight percent of said composition.
39. A method of delivering an active substance to at least one of an oral, an oralpharnygeal, and a nasal membrane by administration through the mouth, the method comprising the steps of:
providing a composition having a pharmaceutically acceptable carrier and a zinc formulation comprising both zinc gluconate and zinc acetate; and applying the composition to the oral cavity by way of an oral spray.
providing a composition having a pharmaceutically acceptable carrier and a zinc formulation comprising both zinc gluconate and zinc acetate; and applying the composition to the oral cavity by way of an oral spray.
40. A method for delivering an active substance to at least one or an oral, an oralpharnygeal, and a nasal membrane by administration through the mouth, the method comprising the steps of:
providing a composition having a pharmaceutically acceptable carrier, zinc gluconate is an amount of about 32-35 mg/ml, and zinc acetate in an amount of about 3-6 mg/ml; and applying the composition to the oral cavity by way of an oral spray.
providing a composition having a pharmaceutically acceptable carrier, zinc gluconate is an amount of about 32-35 mg/ml, and zinc acetate in an amount of about 3-6 mg/ml; and applying the composition to the oral cavity by way of an oral spray.
41. A system for delivering an active substance to at least one of an oral, an oralpharyngeal, and a nasal membrane by administration through the mouth, the system comprising:
a composition having a pharmaceutically acceptable carrier and a zinc formulation comprising both zinc gluconate and zinc acetate; and an oral applicator, wherein the composition is contained within the oral applicator for dispensing an effective dosage into the oral cavity.
a composition having a pharmaceutically acceptable carrier and a zinc formulation comprising both zinc gluconate and zinc acetate; and an oral applicator, wherein the composition is contained within the oral applicator for dispensing an effective dosage into the oral cavity.
42. The system of claim 41, wherein the applicator is configured to deliver a metered dosage to the oral cavity.
43. The system of claim 42, wherein the applicator is an oral spray device.
44. The system of claim 43, wherein the metered dosage delivered to the oral cavity is about .25 mls.
45. A system for reducing cold symptoms and their duration comprising:
a composition having about 84 to about 99.999 weight percent of a pharmaceutically acceptable carrier, about 2 to about 6 weight percent of zinc gluconate, and about 0.2 to about 2.0 weight percent zinc acetate; and an oral applicator, wherein the composition is contained within the oral applicator for dispensing an effective dosage into the oral cavity.
a composition having about 84 to about 99.999 weight percent of a pharmaceutically acceptable carrier, about 2 to about 6 weight percent of zinc gluconate, and about 0.2 to about 2.0 weight percent zinc acetate; and an oral applicator, wherein the composition is contained within the oral applicator for dispensing an effective dosage into the oral cavity.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46721703P | 2003-04-30 | 2003-04-30 | |
| US60/467,217 | 2003-04-30 | ||
| PCT/US2004/013425 WO2004098581A2 (en) | 2003-04-30 | 2004-04-30 | Oral spray to reduce cold symptoms and duration of same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2524074A1 true CA2524074A1 (en) | 2004-11-18 |
| CA2524074C CA2524074C (en) | 2010-03-23 |
Family
ID=33435040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2524074A Expired - Fee Related CA2524074C (en) | 2003-04-30 | 2004-04-30 | Oral composition to reduce cold symptoms and duration of same |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7754763B2 (en) |
| EP (1) | EP1617817B1 (en) |
| AT (1) | ATE373468T1 (en) |
| AU (1) | AU2004235732B2 (en) |
| CA (1) | CA2524074C (en) |
| DE (1) | DE602004009049T2 (en) |
| WO (1) | WO2004098581A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9034401B1 (en) | 2014-01-23 | 2015-05-19 | Matrixx Initiatives, Inc. | Pharmaceutical compositions comprising plant extracts and methods for reducing duration of a common cold using same |
| DE102018205160A1 (en) | 2018-01-12 | 2019-07-18 | Ursapharm Arzneimittel Gmbh | Dietary supplements, uses thereof, methods of supplementation and oral spray |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4138477A (en) | 1976-05-28 | 1979-02-06 | Colgate Palmolive Company | Composition to control mouth odor |
| US5095035A (en) | 1981-07-31 | 1992-03-10 | Eby Iii George A | Flavor stable zinc acetate compositions for oral absorption |
| US4503070A (en) | 1981-07-31 | 1985-03-05 | Eby Iii George A | Method for reducing the duration of the common cold |
| US5409905A (en) | 1981-01-05 | 1995-04-25 | Eby, Iii; George A. | Cure for commond cold |
| US4956385A (en) * | 1981-07-31 | 1990-09-11 | Eby Iii George A | Method for reducing the duration of the common cold |
| USRE33465E (en) | 1981-07-31 | 1990-11-27 | Method for reducing the duration of the common cold | |
| US4758439A (en) | 1984-06-11 | 1988-07-19 | Godfrey Science & Design, Inc. | Flavor of zinc supplements for oral use |
| CA1243952A (en) | 1984-06-11 | 1988-11-01 | John C. Godfrey | Flavor of zinc supplements for oral use |
| DE3431727A1 (en) * | 1984-08-29 | 1986-03-13 | Robugen GmbH Pharmazeutische Fabrik, 7300 Esslingen | Nasal spray for coryza and influenza with a content of zinc gluconate |
| US4689214A (en) | 1985-04-16 | 1987-08-25 | Colgate-Palmolive Company | Composition to counter breath odor |
| US5059416A (en) * | 1989-06-26 | 1991-10-22 | Warner-Lambert Company | Zinc compound delivery system with improved taste and texture |
| US5165914A (en) | 1991-03-04 | 1992-11-24 | David G. Vlock | Oral compositions containing zinc lactate complexes |
| US5094845A (en) | 1991-03-04 | 1992-03-10 | David G. Vlock | Oral compositions containing zinc gluconate complexes |
| ATE281075T1 (en) | 1994-03-28 | 2004-11-15 | Univ Columbia | COMPOSITION FOR INACTIVATE IRRITANTS IN LIQUIDS |
| AU4428397A (en) | 1996-09-20 | 1998-04-14 | Warner-Lambert Company | Oral compositions containing a zinc compound |
| NZ335780A (en) | 1996-10-23 | 2001-01-26 | Univ New York State Res Found | Compositions to control oral microbial oxidation-reduction (Eh) levels and treat gingivitis-periodontitis |
| US5897891A (en) | 1996-11-18 | 1999-04-27 | Godfrey; John C. | Flavorful zinc compositions for oral use incorporating copper |
| DE19818842C1 (en) | 1998-04-28 | 2000-01-05 | Suedzucker Ag | Cold remedy containing sugar alcohol mixture such as Isomalt, having immunostimulant and antimicrobial activity |
| US6169118B1 (en) * | 1998-11-12 | 2001-01-02 | Block Drug Company, Inc. | Flavor blend for masking unpleasant taste of zinc compounds |
| US6183785B1 (en) | 1998-11-12 | 2001-02-06 | Geoffrey J. Westfall | Teat disinfectant |
| DE10124263A1 (en) * | 2001-05-18 | 2003-01-23 | Friedrich A Wetzel | Composition for treating colds comprises zinc sulfate, zinc orotate, zinc gluconate or zinc acetate |
| US6475526B1 (en) | 2001-06-05 | 2002-11-05 | Jeffrey B. Smith | Zinc containing compositions for anti-viral use |
| AU2003216213B2 (en) * | 2002-02-07 | 2008-10-02 | The Trustees Of Columbia University In The City Of New York | Zinc salt compositions for the prevention of mucosal irritation from spermicides and microbicides |
| US20040192587A9 (en) * | 2002-04-23 | 2004-09-30 | Rosenbloom Richard A. | Zinc formulations as a prophylactic treatment for the common cold |
-
2004
- 2004-04-30 DE DE602004009049T patent/DE602004009049T2/en not_active Expired - Lifetime
- 2004-04-30 AT AT04751020T patent/ATE373468T1/en not_active IP Right Cessation
- 2004-04-30 AU AU2004235732A patent/AU2004235732B2/en not_active Ceased
- 2004-04-30 WO PCT/US2004/013425 patent/WO2004098581A2/en active IP Right Grant
- 2004-04-30 US US10/837,078 patent/US7754763B2/en not_active Expired - Fee Related
- 2004-04-30 CA CA2524074A patent/CA2524074C/en not_active Expired - Fee Related
- 2004-04-30 EP EP04751020A patent/EP1617817B1/en not_active Expired - Lifetime
-
2010
- 2010-07-13 US US12/835,646 patent/US8853265B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20050043400A1 (en) | 2005-02-24 |
| AU2004235732B2 (en) | 2008-04-03 |
| DE602004009049T2 (en) | 2008-06-19 |
| ATE373468T1 (en) | 2007-10-15 |
| WO2004098581A2 (en) | 2004-11-18 |
| EP1617817A2 (en) | 2006-01-25 |
| US8853265B2 (en) | 2014-10-07 |
| WO2004098581A3 (en) | 2004-12-09 |
| US7754763B2 (en) | 2010-07-13 |
| US20100280106A1 (en) | 2010-11-04 |
| AU2004235732A1 (en) | 2004-11-18 |
| EP1617817B1 (en) | 2007-09-19 |
| CA2524074C (en) | 2010-03-23 |
| DE602004009049D1 (en) | 2007-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0742714B1 (en) | Liquid pharmaceutical compositions comprising thyroid hormones | |
| JP5116665B2 (en) | Pharmaceutical formulations of apomorphine for buccal administration | |
| US20080031959A1 (en) | Anti-migraine oral spray formulations and methods | |
| AU2007298814B2 (en) | Galenic form for the trans-mucosal delivery of active ingredients | |
| RU2173559C2 (en) | Administration of desmopressin by nasal route | |
| SK2452002A3 (en) | A combination of active agents and use thereof | |
| CZ289395A3 (en) | Transdermic therapeutic system for administration of serotonin agonists | |
| US6620428B1 (en) | Transdermally administered acetylcysteine as mucolytic agent | |
| JP2003176227A (en) | Pharmaceutical composition, method for alleviating tobacco-smoking withdrawal symptom in patient refraining from smoking, and kit for alleviating tobacco- smoking withdrawal symptom in patient | |
| CA2524074A1 (en) | Oral composition to reduce cold symptoms and duration of same | |
| WO2009152369A1 (en) | Pharmaceutical formulation of ketorolac for intranasal administration | |
| US5874450A (en) | Intranasal formulations for promoting sleep and method of using the same | |
| AU742878B2 (en) | Intranasal formulation containing scopolamine and method of treating motion sickness | |
| JPWO2021127070A5 (en) | ||
| US9492546B2 (en) | Use of bethanechol for treatment of Xerostomia | |
| MXPA97000440A (en) | Pharmaceutical composition nasod administrable monodosis and method of application of such composic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20130430 |